{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:56:47Z","timestamp":1767117407169},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,11,16]],"date-time":"2009-11-16T00:00:00Z","timestamp":1258329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,11,16]],"date-time":"2009-11-16T00:00:00Z","timestamp":1258329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1038\/bmt.2009.273","type":"journal-article","created":{"date-parts":[[2009,11,16]],"date-time":"2009-11-16T13:33:56Z","timestamp":1258378436000},"page":"849-855","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants"],"prefix":"10.1038","volume":"45","author":[{"given":"B","family":"George","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Kerridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Gilroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Hertzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Bradstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,11,16]]},"reference":[{"key":"BFbmt2009273_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/asheducation-2007.1.47","volume":"2007","author":"JH Antin","year":"2007","unstructured":"Antin JH . Reduced intensity stem cell transplantation. Hematology Am Soc Hematol Educ Program 2007; 2007: 47\u201354.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFbmt2009273_CR2","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1182\/blood.V99.6.1978","volume":"99","author":"C Junghanss","year":"2002","unstructured":"Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978\u20131985.","journal-title":"Blood"},{"key":"BFbmt2009273_CR3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/sj.bmt.1704164","volume":"32","author":"J Schetelig","year":"2003","unstructured":"Schetelig J, Oswald O, Steuer N, Radonic A, Thulke S, Held TK et al. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant 2003; 32: 695\u2013701.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009273_CR4","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/sj.bmt.1705974","volume":"41","author":"QA Hill","year":"2008","unstructured":"Hill QA, Hill A, Collyns TA, Pearce RM, Cook G . Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41: 749\u2013751.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009273_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00277-003-0706-1","volume":"82","author":"D Nachbaur","year":"2003","unstructured":"Nachbaur D, Larcher C, Kircher B, Eibl G, Nussbaumer W, Gunsilius E et al. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation. Ann Hematol 2003; 82: 621\u2013627.","journal-title":"Ann Hematol"},{"key":"BFbmt2009273_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/sj.bmt.1705701","volume":"40","author":"JS Kalpoe","year":"2007","unstructured":"Kalpoe JS, van der Heiden PL, Vaessen N, Claas EC, Barge RM, Kroes AC . Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning. Bone Marrow Transplant 2007; 40: 137\u2013143.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009273_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/ajh.21215","volume":"83","author":"YS Chae","year":"2008","unstructured":"Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Yang DH et al. Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors. Am J Hematol 2008; 83: 649\u2013653.","journal-title":"Am J Hematol"},{"key":"BFbmt2009273_CR8","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1182\/blood.V99.12.4357","volume":"99","author":"S Chakrabarti","year":"2002","unstructured":"Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O\u2019Gorman P et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1\u2009H in delaying immune reconstitution. Blood 2002; 99: 4357\u20134363.","journal-title":"Blood"},{"key":"BFbmt2009273_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/sj.bmt.1704442","volume":"33","author":"M Mohty","year":"2004","unstructured":"Mohty M, Mohty AM, Blaise D, Faucher C, Bilger K, Isnardon D et al. Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen. Bone Marrow Transplant 2004; 33: 839\u2013846.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009273_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/sj.bmt.1703351","volume":"29","author":"K Nakai","year":"2002","unstructured":"Nakai K, Kanda Y, Mineishi S, Saito T, Ohnishi M, Niiya H et al. Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin. Bone Marrow Transplant 2002; 29: 237\u2013241.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009273_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","volume":"13","author":"K Micklethwaite","year":"2007","unstructured":"Micklethwaite K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 707\u2013714.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009273_CR12","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1182\/blood-2008-06-161695","volume":"112","author":"KP Micklethwaite","year":"2008","unstructured":"Micklethwaite KP, Clancy L, Sandher U, Hansen AM, Blyth E, Antonenas V et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008; 112: 3974\u20133981.","journal-title":"Blood"},{"key":"BFbmt2009273_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1399-3062.2004.00075.x","volume":"6","author":"E Meijer","year":"2004","unstructured":"Meijer E, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK, Verdonck LF . Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis 2004; 6: 171\u2013178.","journal-title":"Transpl Infect Dis"},{"key":"BFbmt2009273_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3346\/jkms.2004.19.2.172","volume":"19","author":"SJ Oh","year":"2004","unstructured":"Oh SJ, Lee KH, Lee JH, Choi SJ, Kim WK, Lee JS et al. The risk of cytomegalovirus infection in non-myeloablative peripheral stem cell transplantation compared with conventional bone marrow transplantation. J Korean Med Sci 2004; 19: 172\u2013176.","journal-title":"J Korean Med Sci"},{"key":"BFbmt2009273_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/sj.bmt.1703648","volume":"30","author":"R Nakamura","year":"2002","unstructured":"Nakamura R, Cortez K, Solomon S, Battiwala M, Gill VJ, Hensel N et al. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 235\u2013242.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009273_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/sj.bmt.1705249","volume":"37","author":"J Kline","year":"2006","unstructured":"Kline J, Pollyea DA, Stock W, Artz A, Rich E, Godley L et al. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant 2006; 37: 307\u2013310.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009273_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/sj.bmt.1705121","volume":"36","author":"R Lamba","year":"2005","unstructured":"Lamba R, Carrum G, Myers GD, Bollard CM, Krance RA, Heslop HE et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant 2005; 36: 797\u2013802.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009273_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1034\/j.1399-3062.2003.00027.x","volume":"5","author":"A Busca","year":"2003","unstructured":"Busca A, Locatelli F, Barbui A, Ghisetti V, Cirillo D, Serra R et al. Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2003; 5: 132\u2013139.","journal-title":"Transpl Infect Dis"},{"key":"BFbmt2009273_CR19","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/blood.V67.4.1162.1162","volume":"67","author":"W Miller","year":"1986","unstructured":"Miller W, Flynn P, McCullough J, Balfour Jr HH, Goldman A, Haake R et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986; 67: 1162\u20131167.","journal-title":"Blood"},{"key":"BFbmt2009273_CR20","first-page":"78","volume":"91","author":"P Ljungman","year":"2006","unstructured":"Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparellid E, Aschan J et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006; 91: 78\u201383.","journal-title":"Haematologica"},{"key":"BFbmt2009273_CR21","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.humimm.2004.02.014","volume":"65","author":"P Moss","year":"2004","unstructured":"Moss P, Khan N . CD8(+) T-cell immunity to cytomegalovirus. Hum Immunol 2004; 65: 456\u2013464.","journal-title":"Hum Immunol"},{"key":"BFbmt2009273_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0923-1811(99)00085-7","volume":"22","author":"Y Kano","year":"2000","unstructured":"Kano Y, Shiohara T . Current understanding of cytomegalovirus infection in immunocompetent individuals. J Dermatol Sci 2000; 22: 196\u2013204.","journal-title":"J Dermatol Sci"},{"key":"BFbmt2009273_CR23","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1182\/blood-2002-05-1387","volume":"100","author":"E Ozdemir","year":"2002","unstructured":"Ozdemir E, St John LS, Gillespie G, Rowland-Jones S, Champlin RE, Molldrem JJ . Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 2002; 100: 3690\u20133697.","journal-title":"Blood"},{"key":"BFbmt2009273_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/sj.bmt.1705585","volume":"39","author":"S Ganepola","year":"2007","unstructured":"Ganepola S, Gentilini C, Hilbers U, Lange T, Rieger K, Hofmann J et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 293\u2013299.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009273_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3324\/haematol.11912","volume":"93","author":"D Lilleri","year":"2008","unstructured":"Lilleri D, Fornara C, Chiesa A, Caldera D, Alessandrino EP, Gerna G . Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 2008; 93: 248\u2013256.","journal-title":"Haematologica"},{"key":"BFbmt2009273_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.clim.2005.12.001","volume":"119","author":"V Ferrari","year":"2006","unstructured":"Ferrari V, Cacere CR, Machado CM, Pannuti CS, Dulley FL, Barros JC et al. Distinct patterns of regeneration of central memory, effector memory and effector TCD8+ cell subsets after different hematopoietic cell transplant types: possible influence in the recovery of anti-cytomegalovirus immune response and risk for its reactivation. Clin Immunol 2006; 119: 261\u2013271.","journal-title":"Clin Immunol"},{"key":"BFbmt2009273_CR27","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1182\/blood-2002-11-3472","volume":"102","author":"M Hakki","year":"2003","unstructured":"Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003; 102: 3060\u20133067.","journal-title":"Blood"},{"key":"BFbmt2009273_CR28","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0301-472X(03)00201-7","volume":"31","author":"M Maris","year":"2003","unstructured":"Maris M, Boeckh M, Storer B, Dawson M, White K, Keng M et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003; 31: 941\u2013952.","journal-title":"Exp Hematol"},{"key":"BFbmt2009273_CR29","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V95.7.2240","volume":"95","author":"AE Broers","year":"2000","unstructured":"Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95: 2240\u20132245.","journal-title":"Blood"},{"key":"BFbmt2009273_CR30","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1046\/j.1365-2141.2001.02849.x","volume":"113","author":"N Kr\u00f6ger","year":"2001","unstructured":"Kr\u00f6ger N, Zabelina T, Kr\u00fcger W, Renges H, Stute N, Kabisch H et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 2001; 113: 1060\u20131071.","journal-title":"Br J Haematol"},{"key":"BFbmt2009273_CR31","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","volume":"111","author":"DJ Winston","year":"2008","unstructured":"Winston DJ, Young JA, Pullarkat V, Papanicolau GA, Vij R, Vance E et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo controlled, dose-ranging study. Blood 2008; 111: 5403\u20135410.","journal-title":"Blood"},{"key":"BFbmt2009273_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bcmd.2007.07.003","volume":"40","author":"S Mackinnon","year":"2008","unstructured":"Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M . Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis 2008; 40: 63\u201367.","journal-title":"Blood Cells Mol Dis"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2009273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2009273","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2009273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T12:16:22Z","timestamp":1648037782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2009273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,16]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["BFbmt2009273"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2009.273","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,16]]},"assertion":[{"value":"1 May 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}